CAMP4 THERAPEUTICS CORPORATION
Ownership
Ownership Structure
Who owns CAMP4 THERAPEUTICS CORPORATION (CAMP)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 61.3% of the shares are freely tradable; institutional investors hold 86.6%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| HHG PLC | 10.05 | 6,307,636 | +0.0 | 03/31/2026 |
| 5AM Venture Management, LLC | 9.35 | 5,869,091 | +0.0 | 06/30/2026 |
| FMR Inc | 7.86 | 4,933,432 | +0.3 | 03/31/2026 |
| Vivo Capital, LLC | 6.77 | 4,246,568 | +0.0 | 06/30/2026 |
| Balyasny Asset Management LLC | 4.19 | 2,632,437 | +8.0 | 03/31/2026 |
| Adage Capital Partners Gp LLC | 3.12 | 1,960,784 | +0.0 | 06/30/2026 |
| Trails Edge Capital Partners, LP | 3.08 | 1,932,937 | -0.3 | 06/30/2026 |
| Vanguard Capital Management, LLC | 2.45 | 1,534,768 | +0.0 | 03/31/2026 |
| Enavate Sciences GP, LLC | 2.27 | 1,425,541 | -34.9 | 06/30/2026 |
| Stonepine Capital Management Llc | 2.21 | 1,389,622 | +507.1 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Schwab Andrew J. | Director | 2,033,270 | 8,133,080 $ | Aug 27, 2026 | indirect |
| Mandel-Brehm Josh | Chief Executive Officer | 284,968 | 1,139,872 $ | Aug 3, 2026 | direct |
| Young Richard A | Director | 186,388 | 745,552 $ | Aug 3, 2026 | direct |
| Gold Kelly | Chief Financial Officer | 84,428 | 337,712 $ | Aug 3, 2026 | both |
| Maricich Yuri | Chief Medical Officer | 12,611 | 50,444 $ | Aug 3, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Gold Kelly | Chief Financial Officer | Buy | 10,000 | 3.96 | 39,600 |
| Aug 27, 2026 | Schwab Andrew J. | Director | Sell | 400,000 | 4.04 | 1,616,000 |
| Aug 24, 2026 | Schwab Andrew J. | Director | Sell | 10 | 4.50 | 45 |
| Aug 21, 2026 | Schwab Andrew J. | Director | Sell | 32,018 | 4.50 | 144,081 |
| Aug 20, 2026 | Schwab Andrew J. | Director | Sell | 114,700 | 4.54 | 520,738 |
| Aug 19, 2026 | Schwab Andrew J. | Director | Sell | 45,147 | 4.76 | 214,900 |
| Aug 19, 2026 | Tardiff Daniel | Chief Scientific Officer | Sell | 1,738 | 4.76 | 8,273 |
| Aug 3, 2026 | Young Richard A | Director | Buy | 16,378 | 1.65 | 27,024 |
| Aug 3, 2026 | Maricich Yuri | Chief Medical Officer | Buy | 6,551 | 1.65 | 10,809 |
| Aug 3, 2026 | Gold Kelly | Chief Financial Officer | Buy | 6,551 | 1.65 | 10,809 |
| Aug 3, 2026 | Mandel-Brehm Josh | Chief Executive Officer | Buy | 6,551 | 1.65 | 10,809 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.